ArticleCardiovascular therapeutics2026
A Multicohort Machine Learning Framework to Predict Mortality in Elderly Patients With Heart Disease: Insights From HARLS, SHARE, and HRS.
Article in Cardiovascular therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Multicohort Machine Learning Framework to Predict Mortality in Elderly Patients With Heart Disease: Insights From HARLS, SHARE, and HRS.Cardiovascular therapeutics · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elderly patients with heart disease face elevated mortality risk, yet predictive models specifically tailored for this population across different global regions remain limited. Current mortality prediction tools often lack cross-cultural validation and interpretability, hindering their clinical application in diverse healthcare settings. Methods: We developed and validated machine learning models for predicting mortality in elderly heart disease patients using data from three major aging cohorts: the China Health and Retirement Longitudinal Study (CHARLS, Results: XGBoost demonstrated superior performance with the highest average AUC (0.798) across all datasets, showing excellent generalizability from the SHARE training set (AUC: 0.805) to internal validation (AUC: 0.799) and external validation in HRS (AUC: 0.821) and CHARLS (AUC: 0.770) cohorts. Age consistently emerged as the most influential predictor across all cohorts (SHAP values: 0.056-0.102), followed by gender, moderate physical activity, and self-rated health, though their relative importance varied by cohort. Feature dependence analysis revealed important nonlinear relationships, including U-shaped associations between grip strength and mortality risk. Conclusion: Our multicohort machine learning approach successfully developed a robust, interpretable model for predicting mortality in elderly heart disease patients across diverse global populations. The model's strong performance in external validation demonstrates its potential for cross-cultural clinical application, while SHAP analysis provides valuable insights into population-specific risk factors that could guide targeted interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.